1056456-02-0

Basic information

• Product Name: (S)-2-ethoxy-3-(4-((5-(3-methoxyphenyl)-3-methylthiophen-2-yl)methoxy)phenyl)propionic acid ethyl ester
• Synonyms: (S)-2-ethoxy-3-(4-((5-(3-methoxyphenyl)-3-methylthiophen-2-yl)methoxy)phenyl)propionic acid ethyl ester
• CAS NO: 1056456-02-0
• Molecular Weight: 454.587
• Mol File: 1056456-02-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (S)-2-ethoxy-3-(4-((5-(3-methoxyphenyl)-3-methylthiophen-2-yl)methoxy)phenyl)propionic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-ethoxy-3-(4-((5-(3-methoxyphenyl)-3-methylthiophen-2-yl)methoxy)phenyl)propionic acid ethyl ester(1056456-02-0)
• EPA Substance Registry System: (S)-2-ethoxy-3-(4-((5-(3-methoxyphenyl)-3-methylthiophen-2-yl)methoxy)phenyl)propionic acid ethyl ester(1056456-02-0)

Safety Data

• Hazardous Substances Data: 1056456-02-0(Hazardous Substances Data)

Upstream product

• 222835-03-2 3-(4-benzyloxy-phenyl)-2-ethoxy-acrylic acid ethyl ester 
• 325793-65-5 (2S)-2-Ethoxy-3-(4-hydroxyphenyl)propanoic acid 
• 222555-06-8 ethyl (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate 
• 197299-16-4 ethyl 2-ethoxy-3-(4-hydroxy-phenyl)-propionate 
• 1056456-28-0 (S)-2-ethoxy-3-(4-((3-methylthiophen-2-yl)methoxy)phenyl)propionic acid ethyl ester 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 63826-56-2 2-Hydroxymethyl-3-methyl-thiophene 
• 5834-16-2 3-methyl-2-thiophenecarboxaldehdye 
• 1056456-04-2 (S)-3-(4-((5-bromo-3-methylthiophen-2-yl)methoxy)phenyl)-2-ethoxypropionic acid ethyl ester 
• 10365-98-7 3-methoxyphenylboronic acid 

Relevant articles and documents

NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention provides a novel phenylpropionic acid derivative and a PPAR-γ modulator comprising the same as an active ingredient. The phenylpropionic acid derivative of the present invention has modulatory action on function of PPAR-γ and then exhibits hypoglycemic, hypolipidemic and insulin resistance-reducing effects on PPAR-mediated diseases or disorders. Therefore, the present invention is prophylactically or therapeutically effective for diabetes and metabolic diseases.